La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Zhejiang Huahai Pharmaceutical Bilan de santé

Santé financière contrôle des critères 5/6

Zhejiang Huahai Pharmaceutical possède un total de capitaux propres de CN¥8.5B et une dette totale de CN¥8.2B, ce qui porte son ratio d'endettement à 96.2%. Son actif total et son passif total sont CN¥20.1B et de CN¥11.6B. L'EBIT de Zhejiang Huahai Pharmaceutical est CN¥1.5B ce qui fait que son ratio de couverture des intérêts 7.8. Elle dispose de liquidités et de placements à court terme de CN¥2.9B.

Informations clés

76.4%

Ratio d'endettement

CN¥6.85b

Dette

Ratio de couverture des intérêts	9.5x
Argent liquide	CN¥1.66b
Fonds propres	CN¥8.96b
Total du passif	CN¥10.55b
Total des actifs	CN¥19.51b

Mises à jour récentes de la santé financière

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

May 28

Recent updates

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 20

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

May 28

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

May 06

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Mar 22

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 600521 ( CN¥8.9B ) dépassent ses passifs à court terme ( CN¥6.7B ).

Passif à long terme: Les actifs à court terme de 600521 ( CN¥8.9B ) dépassent ses passifs à long terme ( CN¥4.9B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 600521 ( 62.1% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de 600521 a été réduit de 93.8% à 76.5% au cours des 5 dernières années.

Couverture de la dette: La dette de 600521 est bien couverte par le flux de trésorerie opérationnel ( 33% ).

Couverture des intérêts: Les paiements d'intérêts de 600521 sur sa dette sont bien couverts par l'EBIT ( 7.8 x couverture).

Zhejiang Huahai Pharmaceutical Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.27 in 2Q 2023)

Consensus EPS estimates increase by 14%

Dividend reduced to CN¥0.20

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

Price target increased by 11% to CN¥18.17

Zhejiang Huahai Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.12 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.57 (vs CN¥0.81 in FY 2022)

Investor sentiment improves as stock rises 18%

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Investor sentiment improves as stock rises 17%

Consensus revenue estimates fall by 10%

Price target decreased by 11% to CN¥17.60

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) announces an Equity Buyback for CNY 100 million worth of its shares.

Consensus EPS estimates fall by 13%

Third quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.16 in 3Q 2022)

Price target decreased by 10% to CN¥20.63

Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.28 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.81 (vs CN¥0.34 in FY 2021)

Consensus EPS estimates increase by 11%

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.053 in 3Q 2021)

Price target increased to CN¥18.00

Second quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.17 in 2Q 2021)

Zhejiang Huahai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.56 billion in funding

Price target increased to CN¥15.50

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in FY 2020)

Price target increased to CN¥15.50

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target increased to CN¥15.50

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.24 in 2Q 2020)

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) announces an Equity Buyback for CNY 200 million worth of its shares.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.15 in 1Q 2020)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.64 (vs CN¥0.41 in FY 2019)

New 90-day low: CN¥28.88

Market bids up stock over the past week

Third quarter 2020 earnings released: EPS CN¥0.18

New 90-day low: CN¥31.49

Price target raised to CN¥12.27

Third quarter earnings released

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 20, 2020

Analysts update estimates

New 90-day low: CN¥31.92

First half earnings released

New 90-day high - CN¥44.83

New 90-day high - CN¥41.96

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines